UPDATE: Seattle Children’s Now Enrolling Participants for First U.S. CAR T Cell Clinical Trial for Children with Systemic Lupus Erythematosus
Seattle Children’s announced they are now enrolling participants in the first CAR T cell clinical trial for children with systemic lupus erythematosus (SLE). This is the first clinical trial in the U.S. examining CAR T cell therapy in a pediatric population.
The phase 1 trial, Reversing Autoimmunity through Cell Therapy, or REACT-01, plans to enroll 12 participants ages 2 to 30 living with lupus that is resistant to current treatment regimens, but the first three participants to enroll must be age 17 or older. CAR-T cells are genetically altered cells that are designed to reset the immune system. CAR-T cell therapy targets B cells, which are immune system cells involved in the production of autoantibodies and lupus disease activity.
Continue to follow the Lupus Foundation of America for updates on the REACT-01 study, as well as other lupus drug development news. Learn more about participating in clinical trials.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.